Targeting Alzheimer’s Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies

Ming Tong1,2,4, Cesar Dominguez*, John Didsbury3 and Suzanne M de la Monte1,7

1Liver Research Center, Warren Alpert Medical School of Brown University, Providence, RI, USA
2Divisions of Gastroenterology, Warren Alpert Medical School of Brown University, Providence, RI, USA
3Department of Pathology, Warren Alpert Medical School of Brown University, Providence, RI, USA
4Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA
5Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA
6Department of Neurosurgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, RI, USA
7Williams College, Williams, MA, USA
8TJ3 Pharmaceuticals, Raleigh Durham, NC, USA

Abstract

Background: Alzheimer’s disease (AD) could be regarded as a brain form of diabetes since insulin resistance and deficiency develop early and progress with severity of neurodegeneration. Preserving insulin’s actions in the brain restores function and reduces neurodegeneration. T3D-959 is a dual nuclear receptor agonist currently in a Phase 2a trial in mild-to-moderate AD patients (ClinicalTrials.gov identifier NCT02560753). Herein, we show that T3D-959 improves motor function and reverses neurodegeneration in a sporadic model of AD.

Methods: Long Evans rats were administered intracerebral (i.c.) streptozotocin (STZ) or normal saline (control) and dosed orally with T3D-959 (1.0 mg/kg/day) or saline for 21 or 28 days. Rotarod tests evaluated motor function. Histopathology with image analysis was used to assess neurodegeneration.

Results: T3D-959 significantly improved motor performance, and preserved both cortical and normalized white matter structure in i.c STZ-treated rats. T3D-959 treatments were effective when dosed therapeutically, whether initiated 1 day or 7 days after i.c. STZ.

Conclusion: T3D-959’s targeting neuro-metabolic dysfunctions via agonism of PPAR delta and PPAR gamma nuclear receptors provides potential disease modification in AD.

Keywords: Alzheimer; T3D-959; PPAR agonist; Type 3 diabetes; Streptozotocin; Motor function; Cerebellum; Neurodegeneration

Introduction

Effective disease modifying therapy is critically needed for the treatment of Alzheimer’s disease (AD). Despite extensive research and large-scale, long-term treatment with drugs that target symptoms including acetylcholinesterase inhibitors, NMDA receptor antagonists and amyloid vaccines, the clinical course of AD has not been significantly remediated. The most likely explanation for these failures is that AD multifaceted and is caused by inter-related cellular, biochemical and molecular abnormalities that culminate in loss of neurons, deposition of amyloid beta, accumulation of phospho-tau-containing neuronal cytoskeletal lesions, activation of cell death cascades, deficits in energy metabolism, mitochondrial dysfunction, increased inflammation, DNA damage and oxidative stress. Importantly, these pathophysiological responses closely resemble effects of insulin resistance and insulin deficiency as occur in diabetes mellitus, except the alterations selectively or predominantly affect the brain. This concept regarding the pathogenesis of AD as a consequence of neuro-metabolic dysfunction led to the term “Type-3 Diabetes” [1,2]. Correspondingly, the earliest abnormalities, preceding the onset of cognitive impairment, include impairments in glucose utilization and energy metabolism [3-5].

After the brain is totally dependent on glucose as an energy source, and reduced brain glucose metabolism is both a hallmark of AD and the future best predictor of cognitive decline [6-9]. Insulin is needed for efficient utilization of glucose by brain cells, and is the master hormone whose signaling regulates major biological responses including: Cell growth, neuronal and oligodendroglial survival, neuronal plasticity, energy metabolism, acetylcholine production, inhibition of oxidative stress, and myelin maintenance. Reductions in brain insulin signaling due to insulin deficiency or insulin receptor resistance could account for the majority of molecular, biochemical, and histopathological lesions, as well as cognitive impairment in AD [2,10-18]. Furthermore, disruption of neuronal insulin signaling networks enhances apoptosis [19,20], promotes oxidative injury induced by Aβ[21], increases secretion of Aβ-oligomers [22], blocks removal of extracellular Aβ-oligomers [23] and increases plaque burden [24].

Growing evidence suggests that brain insulin resistance promotes or triggers key pathologies in AD [2,3,11,25-34], corresponding with the observed changes in levels of insulin signaling molecules in AD forebrains and associated declines in memory [2,11,12,27,32,34-36]. What is particularly alarming is that peripheral insulin resistance,

*Corresponding author: Suzanne M de la Monte, Pierre Galletti Research Building, Rhode Island Hospital, 55 Claverick Street, Room 419, Providence, RI, USA, Tel: 401-444-7364; Fax: 401-444-2939; E-mail: Suzanne_DeLaMonte_MD@Brown.edu

Received May 02, 2016; Accepted May 27, 2016; Published June 03, 2016


Copyright: © 2016 Tong M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Intracerebral Streptozotocin (STZ) neurodegeneration in structural targets of brain insulin resistance in AD [2,58], insulin signaling is an important regulator of cerebellar structure and function [59], and the cerebellum likely requires treatment of multiple molecular and biochemical targets [25,26,37,42,43]. Two approaches were used to extract information about neurodegeneration in AD [54]. Therefore, two approaches were used to extract information about neurodegeneration in AD. T3D-959 was formulated as a solution in 0.9% NaCl at a concentration of 4.44 mg/ml and prepared fresh daily. Rats were treated by oral gavage with 1.0 mg/kg T3D-959 or normal saline vehicle, once daily from 1 day or 7 days after the i.c. STZ or vehicle treatments. Oral gavage was performed using a ball ended feeding needle to inject drug or vehicle.

Rotarod studies

We used rotarod tests to assess long-term effects of i.c. STZ treatment and the therapeutic effects of T3D-959 on motor function [73]. Rats were administered 10 trials at incremental speeds up to 10 rpm, with 10 min rest between trials. The latency to fall was automatically detected and recorded with photocells placed over the rod. Trials were stopped after 30 s to avoid exercise fatigue. Data from trials 1-3 (2-5 rpm), 4-7 (5-7 rpm), and 8-10 (8-10 rpm) were culled and analyzed using the Mann-Whitney test.

Histological and image analysis studies

The rats were sacrificed by isoflurane inhalation. Cerebella were cut in the mid-sagittal plane, weighed, immersion fixed in 10% formalin, and embedded in paraffin. Histological sections (4 μm thick) generated 5 mm from the midline were stained with Luxol Fast Blue, hematoxylin and eosin (LHE) and used for histopathological assessments and image analysis. Assessments of regional brain atrophy can be achieved by several approaches that may differ in sensitivity, including measurement of cortical thickness and cross-sectional area [74]. Therefore, two approaches were used to extract information about cortical and white matter thicknesses in relation to i.c. STZ and T3D-959 treatment: 1) image analysis to measure cross-sectional areas; and 2) semi-quantitative assessments of cortical and white matter thicknesses and cellularity within the granule and Purkinje cell layers. ImageJ/Fiji was used to determine cross-sectional areas of the entire slice, molecular and granule cell layers, and white matter (Figure 1). All slides analyses were performed under code.

Statistics

Graphs depict group means and standard deviations. Inter-group comparisons were made using one-way or two-way analysis of variance (ANOVA) and the Tukey post hoc test (GraphPad Prism 6, San Diego, CA).

Results

T3D-959 treatments restore i.c. STZ-mediated impairments of motor function

Rotarod data were grouped and analyzed using the Mann-Whitney
H&E stained sections of cerebellar vermis were graded using the semi-quantitative criteria indicated in the table. The mean scores obtained for each layer were compared across the 4 experimental groups by two-way ANOVA (see Figure 5).

Table 1: Semi-quantitative grading of cerebellar vermis histopathology.

<table>
<thead>
<tr>
<th>Cortical Layer</th>
<th>Grade 4</th>
<th>Grade 3</th>
<th>Grade 2</th>
<th>Grade 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular</td>
<td>Uniformly thick and cellular</td>
<td>Variable thinning, normal cellularity</td>
<td>Variable thinning and reduced cellularity</td>
<td>Uniformly thin</td>
</tr>
<tr>
<td>Purkinje</td>
<td>Well populated with histologically intact pyramidal neurons</td>
<td>Isolated neuronal loss or eosinophilic degeneration (necrosis)</td>
<td>Moderate gaps and scattered loss of neurons</td>
<td>Large gaps and conspicuously increased neuronal necrosis</td>
</tr>
<tr>
<td>Granule</td>
<td>Uniformly thick and densely cellular</td>
<td>Irregular thinning but densely cellular</td>
<td>Irregular thinning with modest reductions in cell density</td>
<td>Irregular thinning and conspicuous reductions in cell density</td>
</tr>
</tbody>
</table>

T3D-959 rescue of i.c. STZ-mediated of motor impairment. Long Evans rats were administered i.c. STZ or normal saline (Control). The control rats and a subset of the i.c. STZ rats were gavage with saline. Two other sub-groups of i.c. STZ rats were gavage with a single daily dose of 1.0 mg/kg of T3D-959 beginning 1 day or 7 days after the i.c. STZ injections. Sixteen days later, the rats were subjected to Rotarod testing with 10 incremental speed trials. Latency to fall was measured optically. Data culled from Trials (A) 1-4, (B) 5-6, and (C) 8-10 are depicted in the graphs (mean ± S.E.M. per group/trial). Inter-group comparisons were made using the Mann-Whitney test. *P<0.05; **P<0.01; ****P<0.0001.
under code using semi-quantitative assessments (Table 1). The mean effects of STZ and T3D treatments on cerebellar vermis architecture using a semi-quantitative grading scheme to systematically assess reflected by the image analysis results, we evaluated the tissue sections remained irregularly thinned. These results suggest that T3D may be cell density within the granule layer, the granule cell layer thickness (Figures 4C, 4D, 4G and 4H). But, did not restore the thickness of the molecular layer thickness, reduced populations of Purkinje cells with large gaps corresponding to regions of neuronal loss, as well as multiple neurons exhibiting shrinkage and eosinophilia reflecting ongoing necrosis. In addition, i.c. STZ caused irregular thinning of the granule cell layer and white matter cores (Figures 4B and 4E). T3D-959 treatments initiated either 1 day or 7 days post i.c. STZ increased the molecular layer thickness, reduced neuronal loss and necrosis in the Purkinje layer, and expanded the white matter core thickness (Figures 4C, 4D, 4G and 4H). But, did not restore the thickness of the granule cell layer. Although T3D treatment conspicuously increased cell density within the granule layer, the granule cell layer thickness remained irregularly thinned. These results suggest that T3D may be neuroprotective for both granule and Purkinje cells.

Semi-quantitative histological grading of cerebellar structure

Since the histological abnormalities in the cortex were not well reflected by the image analysis results, we evaluated the tissue sections using a semi-quantitative grading scheme to systematically assess effects of STZ and T3D treatments on cerebellar vermis architecture (Table 1). H&E stained sections of cerebellar vermis were scored under code using semi-quantitative assessments (Table 1). The mean ± S.D. scores corresponding to uniformity and thickness of the molecular layer, cellularity of the Purkinje layer, and thickness and cellularity of the granule cell layer are depicted in Figure 5. Two-way ANOVA demonstrated significant inter-group differences with respect to all three regions of cortex. STZ treatment significantly reduced the thickness and uniformity of the molecular layer, and cellularity in the Purkinje and granule cell layers relative to control (Figure 5). The differences in molecular layer thickness and Purkinje cellularity relative to control remained significant for the group that was treated with T3D-959 beginning 1 day after i.c. STZ. However, cellularity and thickness uniformity of the granule cell layer were restored by early treatment with T3D-959. Furthermore, T3D-959 treatment beginning 7 days after i.c. STZ restored or preserved the integrity of all three cortical layers relative to control.

Discussion

Since 2005, over 60 published works have shown that the i.c. STZ model of brain diabetes mimics most aspects of sporadic AD with respect to molecular, biochemical, histopathological, and/or neurobehavioral abnormalities [1,54,75-78]. In this regard, the i.c. STZ model causes amyloid-β deposition, pTau accumulation, cortical-limbic pathway degeneration, deficits in spatial learning and memory, neuro-inflammation, and oxidative stress in the brain, including in regions that are characteristically damaged in AD. In addition, the data show the importance of brain insulin resistance as a mediator of neurodegeneration and amyloid deposition, and vice versa [28,29,36,44,79,80].

Figure 3: Effects of T3D-959 on i.c. STZ-induced alterations in cerebellar structure. Long Evans male rats (4-weeks old) were used to generate a sporadic model of AD by i.c. STZ. The rats (n=6-8 per group) were treated with saline or 1 mg/kg of T3D-959 by daily oral gavage. Rats were sacrificed on Experimental day 28. (A) Fresh cerebellar weights in rats treated with i.c. saline (Con), i.c.-STZ (STZ), T3D-959 beginning 1 day after i.c. STZ (STZ T3D-1), or T3D-959 beginning 7 days after i.c.-STZ (STZ T3D-7). After formalin-fixation, cerebella were cut in the mid-sagittal plane and embedded in paraffin. Histological sections (4 μm thick) stained with hematoxylin and eosin (H&E) were used for image analysis (Image-J) to measure relative cross-sectional areas (percentages of overall area) of the (B) molecular layer, (C) granule cell layer, and (D) white matter. All graphs depict the mean ± S.E.M. of results. Inter-group comparisons were made by one-way ANOVA with the Tukey post-hoc significance test. F-ratios are indicated in the panels. Significant inter-group differences are specified.

Figure 4: T3D-959 Prevents STZ-induced neurodegeneration. H&E stained sections of the cerebellar vermis from rats treated with (A, E) i.c. saline or (B-D, F-H) i.c. STZ, and then treated with (A, B, E, F) vehicle (saline) or (C, D, G, H) 1 mg/kg/day T3D by gavage. T3D after delays of (C, G) 1 day or (D, H) 7 days. Rats were sacrificed 4 weeks after i.c. STZ or vehicle injections. Cerebella were fixed in formalin, embedded in paraffin and sectioned (4 μ thick). (A, E) Control cerebella had relatively thick and uniform molecular (black bars) and granule cell (red bars, yellow ‘G’), (E) well populated Purkinje cell layers (black arrows), and uniform white matter cores (green bars). Relative to control, i.c. STZ treatment caused cortical atrophy with (B) thinning of the molecular and (B, F) granule cell layers, (F) loss (bracket) and on-going necrosis (red arrows) of Purkinje cells, and modest reductions in white matter thickness. (C, D, G, H) T3D-959 normalized or expanded the molecular layer and increased white matter core thickness, reduced cell loss and necrosis in the Purkinje layer, but did not reverse the irregular thinning and neuronal loss in the granule cell layer. Original magnification: (A-D) 100x; (E-H) 425x.
In conclusion, this study demonstrates that T3D-959 has cleared apoptosis at 10 micro-M but not 500 nM. Our experimental conditions produced nM tissue concentrations of T3D-959 [54]. Interestingly, the manuscript by Rohn et al. [82] does show nice neurite process extension and improved neuronal viability at the lowest doses of the PPARgamma agonist used, 15-PGJ2. Furthermore, 15d-PGJ2 [82] is not a selective PPAR gamma agonist as it also interacts with GPR44; acting through this receptor inhibits hair growth. The high doses of 15d-PGJ2 needed to induce apoptosis are not biologically relevant and can produce off-target effects. In addition, this compound acts as a PGE2 receptor agonist with an EC50 of 10nM, and can have PPAR gamma–independent effects [83], calling into question the conclusion that the PPAR gamma activation caused neuronal apoptosis. In contrast, T3D-959 has been demonstrated to increase cell survival (see Figure 4a and article by Tong et al. [54]).

The preclinical studies reported herein assessed the neurobehavioral effects of T3D-959 in an established model of sporadic AD in which adult Long Evans rats were treated by i.c. STZ which is known to cause neurodegeneration, impairments in brain insulin and insulin-like growth factor (IGF) signaling, and increased oxidative stress [10,16]. In addition to assessing T3D-959’s efficacy, we examined responses to early and late therapeutic intervention. The delayed time point of initiating treatment addresses the fact that many people are first diagnosed at clinically intermediate rather than early stages of disease. At the same time, it was important to assess responses to early intervention because as diagnostic tools improve, early treatment protocols will become feasible.

The rotarod tests demonstrated that i.c. STZ impaired cerebellar motor function and that T3D-959 prevented this effect along with neurodegeneration. It was of further interest that these therapeutic responses to T3D-959 were similar and slightly better when treatment was initiated 7 days as opposed to 1 day post i.c. STZ. Histopathological studies demonstrated that the i.c. STZ mediated neuronal loss in Purkinje and granule cell layers and atrophy of white matter were reversed by T3D-959 treatment. Therefore, the neuroprotective effects of T3D-959 correlate with preservation of motor function.

The therapeutic effects of T3D-959 on cerebellar structure and function correspond with the abundant expression of insulin receptors in the cerebellum [59]. Previous studies using various experimental models showed that inhibition of insulin signaling in the cerebellum or cerebellar neurons correlates with neuronal loss and impaired motor function [17,60,62]. In addition, earlier studies showed that treatment with a PPAR-γ agonist effectively restored cerebellar structure and function [10], consistent with findings in the present study. An additional novel finding was the reversal of white matter atrophy in T3D-959 treated i.c. STZ exposed rats. This observation is of particular interest because myelin-producing oligodendrocytes are maintained by insulin/IGF signaling, and increased oxidative stress [10,16]. In addition, our results suggest that motor impairments mediated by neuronal loss and white matter atrophy in AD may be ameliorated by T3D-959 therapy.

In conclusion, this study demonstrates that T3D-959 has cleared therapeutic and neuroprotective effects in an established model of sporadic AD. The main effects were associated with improved (normalized) motor function and reversal of cerebellar degeneration. Importantly, therapeutic effects occurred even after a delay in treatment, suggesting that individuals with mild or moderate AD would benefit from this highly effective small molecule drug that has the benefit of oral, once-daily delivery.
Acknowledgement

Supported by AA-011431 and AG-049510 from the National Institutes of Health.

References


51. de la Monte SM, Tong M, Wands JR (2010) Therapeutic rescue of alcoholic neurodegeneration with PPAR agonists.


